Pseudomonas cepacia.
P. cepacia is reported to be an increasing cause of infection and colonization of patients in hospitals. Historically it is  an important contaminant in the pharmaceutical industry. Its nutritional versatility, ability to survive and multiply in water, high intrinsic resistance to antibiotics, and ability to multiply in the majority of traditional disinfectants make it a superb agent for causing nosocomial infection. Recognition of its differences from P. aeruginosa and its ability to contaminate agents used in hospitals is important in proper treatment and infection control.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D003428:Cross Infection / Q000382:microbiology*; D004202:Disinfectants; D004338:Drug Combinations / Q000627:therapeutic use; D004340:Drug Contamination; D004352:Drug Resistance, Microbial; D004697:Endocarditis, Bacterial / Q000382:microbiology; D005533:Foot Dermatoses / Q000382:microbiology; D006801:Humans; D010860:Pigments, Biological / Q000096:biosynthesis; D011549:Pseudomonas / Q000145:classification / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism / Q000472:pathogenicity; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology*; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014774:Virulence
D000900:Anti-Bacterial Agents; D004202:Disinfectants; D004338:Drug Combinations; D010860:Pigments, Biological; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole